Literature DB >> 21789340

[Scintigraphically "hot" thyroid nodules mainly go hand in hand with a normal TSH].

Rainer Görges1, T Kandror, S Kuschnerus, M Zimny, R Pink, H Palmedo, A Hach, H Rau, C Tanner, K Zaplatnikov, A Bockisch, L Freudenberg.   

Abstract

AIM: In recent years, various professional societies published guidelines for diagnostic evaluation of thyroid nodules, in which the indication for scintigraphy is restricted to patients with subnormal TSH values. It is seen controversial whether such recommendations should be transferred to Germany, partly because of lower iodine intake in this country and the consequent higher percentage of autonomous thyroid nodules, which are not accompanied by a measurable dysfunction. Since reliable data to this topic are scarce, we analyzed multicentrically the spectrum of scintigraphically "hot" and "warm" nodules under the current epidemiological conditions. PATIENTS,
METHODS: In 10 German nuclear medicine out-patient institutions we evaluated the diagnostic data from a total of 514 patients, in whom unequivocally hyperfunctional nodules (focal increased uptake in comparison to perinodular tissue with a sonographically nodular correlative ≥1 cm) could be detected by (99m)Tc-pertechnetate scintigraphy. To minimize selection bias, the surveys were not carried out in hospitals.The recorded parameters included the thyroid hormone levels, the global (99m)Tc-uptake (TcTU), the size of each nodule and the total autonomous nodular volume (V(aut)).
RESULTS: Only 20% of the patients with "hot" nodules had subnormal TSH levels (<0.1 to 0.33 mU / l), the remaining patients had TSH levels from 0.34 to 3.5 mU /l (in one third of the patients TSH levels even exceeded 1.0 mU/l). Moreover, we found no relevant correlation between TSH and TcTU or V(aut).
CONCLUSIONS: In Germany, in at far the largest proportion of patients with autonomous thyroid nodules objectified by means of scintigraphy, TSH levels are within the normal range. Since such nodules with maximum safety can be classified as benign, a corresponding scintigraphic finding has a high priority for the patient. These current data support that it is not reasonable to restrict scintigraphy to patients with subnormal TSH values in this country.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789340     DOI: 10.3413/nukmed-0386-11-02

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  5 in total

1.  Better diagnostics and treatment.

Authors:  Holger Palmedo; Andreas Tüürler
Journal:  Dtsch Arztebl Int       Date:  2014-04-18       Impact factor: 5.594

2.  Searching for the most effective thyrotropin (TSH) threshold to rule-out autonomously functioning thyroid nodules in iodine deficient regions.

Authors:  Luca Giovanella; Federica D'Aurizio; Alfredo Campenni'; Rosaria Maddalena Ruggeri; Sergio Baldari; Frederik Anton Verburg; Pierpaolo Trimboli; Luca Ceriani
Journal:  Endocrine       Date:  2016-09-15       Impact factor: 3.633

Review 3.  Is there still a role for thyroid scintigraphy in the workup of a thyroid nodule in the era of fine needle aspiration cytology and molecular testing?

Authors:  Rodrigo Moreno-Reyes; Aglaia Kyrilli; Maria Lytrivi; Carole Bourmorck; Rayan Chami; Bernard Corvilain
Journal:  F1000Res       Date:  2016-04-27

4.  Fusion iENA Scholar Study: Sensor-Navigated I-124-PET/US Fusion Imaging versus Conventional Diagnostics for Retrospective Functional Assessment of Thyroid Nodules by Medical Students.

Authors:  Martin Freesmeyer; Thomas Winkens; Luis Weissenrieder; Christian Kühnel; Falk Gühne; Simone Schenke; Robert Drescher; Philipp Seifert
Journal:  Sensors (Basel)       Date:  2020-06-17       Impact factor: 3.576

5.  Prevalence of hyperfunctioning thyroid nodules among those in need of fine needle aspiration cytology according to ATA 2015, EU-TIRADS, and ACR-TIRADS.

Authors:  Benjamin Noto; Maria Eveslage; Michaela Pixberg; José Manuel Gonzalez Carvalho; Michael Schäfers; Burkhard Riemann; Peter Kies
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-09       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.